Efectiveness and safety of switching to raltegravir-based regimen in dyslipidemic HIV-infected patients receiving antiretroviral therapy at Arriaran Foundation
Efectividad y seguridad del cambio a esquema basado en raltegravir en pacientes con infección por VIH dislipidémicos bajo terapia antirretroviral en Fundación Arriarán
| dc.contributor | en-US | |
| dc.contributor | No hubo fuentes de financiamiento externo | es-ES |
| dc.creator | Ocampo, Renato | |
| dc.creator | Vera, Désirée | |
| dc.creator | Wolff, Marcelo | |
| dc.date | 2019-08-25 | |
| dc.date.accessioned | 2019-09-11T13:36:47Z | |
| dc.date.available | 2019-09-11T13:36:47Z | |
| dc.identifier | http://revinf.cl/index.php/revinf/article/view/98 | |
| dc.identifier.uri | https://revistaschilenas.uchile.cl/handle/2250/108999 | |
| dc.description | Background: The impact of switching antiretroviral therapy (ART) regimen for dyslipidemia management in HIV-infected (HIV+) patients has not been reported in Chile. Aim: To assess effectiveness and safety at 12 months after switching to raltegravir-based regimen for dyslipidemia management. Methods: Retrospective cohort of HIV+ patients receiving ART at Arriaran Foundation, with dyslipidemia switched to raltegravir-based regimen for lipid management. Results: 73 patients were included, receiving ART based in nonnucleoside reverse transcriptase inhibitor (NNRTI; 50,7%) or protease inhibitor (PI; 49,3%), with mixed dyslipidemia (42,5%) or isolated hypertriglyceridemia (57,5%). At baseline, median total cholesterol (TC) and triglycerides (TG) were 228 mg/dl and 420 mg/dl, respectively; undetectable viral load (VL) was present in 94,5% of patients. Backbone ART was switched in 58,4% and lipid-lowering therapy was used by 89,1% of them. At 12 months, there was a significant decrease in TG (-43,6%) and TC (-19,3%). No cases of virologic failure were observed, although 10,9% of patients had detectable VL at 12 months, mostly transient. Conclusions: Switching ART to raltegravir-based regimen in dyslipidemic patients receiving NNRTI or PI is associated with a significative decrease in TG and TC at 12 months. This strategy is safe, but VL can be increased temporarily. | en-US |
| dc.description | Introducción: El impacto del cambio de terapia antirretroviral (TAR) para tratar la dislipidemia en pacientes infectados por VIH (VIH+) no ha sido reportado en Chile. Objetivo: Evaluar la efectividad y seguridad a 12 meses del cambio de TAR a esquema con raltegravir (RAL), para tratar la dislipidemia.Material y métodos: Cohorte retrospectiva de pacientes VIH+ en TAR, atendidos en Fundación Arriarán, con dislipidemia y que cambiaron a esquema con RAL para tratarla.Resultados: Se incluyó 73 casos, en TAR con inhibidores no nucleosídicos de transcriptasa reversa (INNTR; 50,7%) o inhibidores de proteasa (IP; 49,3%), con dislipidemia mixta (42,5%) o hipertrigliceridemia aislada (57,5%). La mediana de colesterol total (CT) y triglicéridos (TG) basales era 228 mg/dl y 420 mg/dl, respectivamente. El 94,5% tenía carga viral (CV) indetectable. Se modificó TAR de base en 58,4%; 89,1% recibía hipolipemiantes. Los niveles de lípidos descendieron significativamente a 12 meses (TG= -43,6%; CT= -19,3%). Ningún paciente presentó fracaso virológico, aunque 10,9% tuvo viremia detectable a 12 meses, mayoritariamente transitoria.Conclusiones: El cambio de TAR a RAL en pacientes dislipidémicos tratados con INNTR o IP reduce significativamente los niveles de TG y CT a 12 meses. Es una estrategia segura, pero puede observarse viremia transitoria. | es-ES |
| dc.format | application/pdf | |
| dc.language | spa | |
| dc.publisher | Sociedad Chilena de Infectología | es-ES |
| dc.relation | http://revinf.cl/index.php/revinf/article/view/98/224 | |
| dc.relation | http://revinf.cl/index.php/revinf/article/downloadSuppFile/98/44 | |
| dc.relation | http://revinf.cl/index.php/revinf/article/downloadSuppFile/98/45 | |
| dc.rights | Copyright (c) 2019 Revista Chilena de Infectología | es-ES |
| dc.rights | https://creativecommons.org/licenses/by-sa/4.0 | es-ES |
| dc.source | Revista Chilena de Infectología; Vol. 36, Núm. 4 (2019) | es-ES |
| dc.source | 0717-6341 | |
| dc.source | 0716-1018 | |
| dc.subject | en-US | |
| dc.subject | HIV; dyslipidemia; antiretroviral therapy switching; raltegravir; total cholesterol; triglycerides | en-US |
| dc.subject | Infección por VIH/SIDA | es-ES |
| dc.subject | VIH; dislipidemia; cambio de terapia antirretroviral; raltegravir; colesterol total; triglicéridos | es-ES |
| dc.title | Efectiveness and safety of switching to raltegravir-based regimen in dyslipidemic HIV-infected patients receiving antiretroviral therapy at Arriaran Foundation | en-US |
| dc.title | Efectividad y seguridad del cambio a esquema basado en raltegravir en pacientes con infección por VIH dislipidémicos bajo terapia antirretroviral en Fundación Arriarán | es-ES |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
| dc.type | es-ES | |
| dc.type | Cohorte retrospectiva con componentes descriptivos y analíticos | es-ES |
| dc.type | en-US |
This item appears in the following Collection(s)
-
Revista Chilena de Infectología
[0-9]{4}